التفاصيل البيبلوغرافية
| العنوان: |
DETECTION OF A BLOOD COAGULATION ACTIVITY MARKER IN A BODY FLUID SAMPLE |
| Document Number: |
20100129841 |
| تاريخ النشر: |
May 27, 2010 |
| Appl. No: |
12/693129 |
| Application Filed: |
January 25, 2010 |
| مستخلص: |
The invention relates to a method for detecting in a body fluid sample at least one blood coagulation activity marker that reflects the blood coagulation activity of an individual. By correlating the amount or concentration of the blood coagulation activity marker present e.g. in a urine sample, it is possible to monitor the blood coagulation activity of a patient following surgery without having to obtain a blood sample from said patient. |
| Inventors: |
Lassen, Michael Rud (Rungsted Kyst, DK); Borris, Lars C. (Arhus C, DK) |
| Claim: |
1. Method of determining blood coagulation activity of an individual, said method comprising the steps of i) providing a spot urine sample comprising at least one blood coagulation activity marker from said individual, and ii) labeling said marker, from said sample, with a detectable label, whereby the amount of said marker in said sample may be determined, iii) determining the amount of said marker present in said spot urine sample, relative to a predetermined spot urine marker amount cut-off point; and iv) comparing said determined spot urine marker amount with the predetermined spot urine marker amount cut-off point, wherein presence of the marker above the cut-off point indicates a hypercoagulate state and presence of the marker below the cut-off point indicates no hypercoagulate state; and v) based on the comparison of step iii), determining whether said individual is in a hypercoagulate state, said cut-off point being based on a previously determined correlation between the amount of the marker in spot urine samples of reference individuals with known coagulation states with whether those reference individuals are in a hypercoagulate state wherein said marker is selected from the group consisting of peptides comprising pro-thrombin Fragment 1+2 (F1+2), peptides comprising pro-thrombin Fragment 1 (F1), and peptides comprising pro-thrombin Fragment 2 (F2). |
| Claim: |
2. Method of claim 50, wherein said determination in step iii) is obtainable by a method of determining the amount of at least one blood coagulation activity marker which comprises the steps of a) contacting at least a part of said spot urine sample comprising said blood coagulation activity marker with at least one quantifiably detectable reporter species, b) operably linking said blood coagulation activity marker comprised in said spot urine sample to said at least one quantifiably detectable reporter species, c) detecting said at least one quantifiably detectable reporter species operably linked to said blood coagulation activity marker comprised in said spot urine sample by directly or indirectly linking at least one label to said reporter species, said at least one label being capable of developing a visible color which indicates the presence of the marker. |
| Claim: |
3. Method of monitoring the blood coagulation activity of an individual, said method comprising obtaining a plurality of individual determinations of said blood coagulation activity of said individual, wherein each determination of said blood coagulation activity is obtainable by the method of claim 1. |
| Claim: |
4. Method of monitoring the blood coagulation activity of an individual, said method comprising obtaining a plurality of individual determinations of said blood coagulation activity of said individual, wherein each determination of said blood coagulation activity is obtainable by the method of claim 2. |
| Claim: |
5. Method of claim 1 wherein said cut-off point is at least 0.1 nM of the marker. |
| Claim: |
6. Method of claim 1 wherein said cut-off point is 0.30 nM of said marker. |
| Claim: |
7. Method of claim 1, wherein said marker is selected from peptides comprising pro-thrombin Fragment 1+2 (F1+2). |
| Claim: |
8. Method of claim 1, wherein said marker is selected from peptides comprising pro-thrombin Fragment 1 (F1). |
| Claim: |
9. Method of claim 1, wherein said marker is selected from peptides comprising pro-thrombin Fragment 2 (F2). |
| Claim: |
10. Method of claim 1, wherein said marker essentially consists of pro-thrombin Fragment 1+2 (F1+2). |
| Claim: |
11. Method of claim 1, wherein said marker essentially consists of pro-thrombin Fragment 1 (F1). |
| Claim: |
12. Method of claim 1, wherein said marker essentially consists of pro-thrombin Fragment 2 (F2). |
| Claim: |
13. Method of claim 1, wherein said marker comprises amino acid residues 1 to 271 of pro-thrombin of SEQ ID NO:1. |
| Claim: |
14. Method of claim 1, wherein said marker is pro-thrombin Fragment 1 (F1) comprising amino acid residues 1 to 155 of pro-thrombin, including any functional variant thereof being at least 95% identical to said sequence, said functional variant being obtained by deletion, insertion or substitution of at least one amino acid. |
| Claim: |
15. Method of claim 1, wherein said marker is pro-thrombin Fragment 2 (F2) comprising amino acid residues 156 to 271 of pro-thrombin, including any functional variant thereof being at least 95% identical to said sequence, said variant being obtained by deletion, insertion or substitution of at least one amino acid. |
| Claim: |
16. Method of claim 1, wherein said marker is detectable by a reporter species capable of detecting any of pro-thrombin Fragment 1+2 (F1+2), pro-thrombin Fragment 1 (F1), and pro-thrombin Fragment 2 (F2). |
| Claim: |
17. Method of claim 1, wherein said blood coagulation activity marker is selected from the group consisting of peptides comprising a fragment of fibrinogen. |
| Claim: |
18. Method of claim 17, wherein said marker is selected from the group consisting of peptides comprising fibrinopeptide A (FpA). |
| Claim: |
19. Method of claim 17, wherein said marker is fibrinopeptide A (FpA). |
| Claim: |
20. Method of claim 1, wherein said marker is detectable by a reporter species capable of detecting fibrinopeptide A (FpA). |
| Claim: |
21. Method of claim 1, wherein said marker is selected from the group consisting of peptides comprising the carboxy-terminal 17 amino acid residues of the heavy chain of Factor Xa. |
| Claim: |
22. Method of claim 2, wherein said reporter species comprises at least one targeting species. |
| Claim: |
23. Method of claim 22, wherein said targeting species comprises at least one antibody, or a binding fragment thereof, capable of detecting at least one blood coagulation marker defined by an antibody against F1+2. |
| Claim: |
24. Method of claim 22, wherein said targeting species comprises at least one antibody, or a binding fragment thereof, capable of detecting at least one blood coagulation marker defined by an antibody against F1. |
| Claim: |
25. Method of claim 22, wherein said reporter species comprises at least one antibody, or a binding fragment thereof, capable of detecting at least one blood coagulation marker defined by an antibody against F2. |
| Claim: |
26. Method of claim 22, wherein said targeting species comprises at least one antibody capable of detecting at least one blood coagulation marker defined by an antibody against FpA. |
| Claim: |
27. Method of claim 22, wherein said targeting species comprises at least one antibody capable of detecting at least one blood coagulation marker defined by an antibody against Xa. |
| Claim: |
28. Method of claim 23, wherein the targeting species is immobilised on said solid surface. |
| Claim: |
29. Method of claim 28, wherein said solid surface is comprised within a lateral flow device. |
| Claim: |
30. Method of claim 28, wherein said solid surface is a dipstick or part thereof. |
| Claim: |
31. Method of claim 28, wherein said solid surface is nitrocellulose. |
| Claim: |
32. Method of claim 28, wherein said solid surface is comprised within a micro fluid device. |
| Claim: |
33. Method of claim 23, wherein said at least one antibody comprises a polyclonal antibody. |
| Claim: |
34. Method of claim 20, wherein said reporter species further comprises at least one polypeptide operably linked to said at least one targeting species. |
| Claim: |
35. Method of claim 34, wherein said polypeptide comprises an enzyme. |
| Claim: |
36. Method of claim 35, wherein said enzyme comprises a peroxidase activity. |
| Claim: |
37. Method according claim 22, wherein said reporter species further comprises at least one coloured dye molecule. |
| Claim: |
38. Method of claim 37, wherein said at least one coloured dye molecule is rhodamine. |
| Claim: |
39. Method of claim 22, wherein said reporter species comprises two antibodies. |
| Claim: |
40. Method of claim 22, wherein said reporter species comprises a polymeric carrier molecule. |
| Claim: |
41. Method of claim 1, wherein the spot urine sample is a morning sample. |
| Claim: |
42. Method of claim 10, wherein the cut-off point is about 0.3 nmol/liter. |
| Claim: |
43. The method of claim 1, wherein the correlation between the level of said blood coagulation activity marker in spot urine and the level of said blood coagulation activity marker in blood, is characterized by a Spearman rho correlation of at least 0.3. |
| Claim: |
44. The method of claim 1, wherein the correlation between the level of said blood coagulation activity marker in spot urine and the level of said blood coagulation activity marker in blood, is characterized by a Spearman rho correlation of at least 0.4. |
| Claim: |
45. The method of claim 1, wherein the correlation between the level of said blood coagulation activity marker in spot urine and the level of said blood coagulation activity marker in blood, is characterized by a Spearman rho correlation of at least 0.43. |
| Claim: |
46. The method of claim 1, wherein the correlation between the level of said blood coagulation activity marker in spot urine and the level of said blood coagulation activity marker in blood, is characterized by a Spearman rho correlation of about 0.438. |
| Claim: |
47. The method of claim 1, wherein the Spearman rho correlation between the level of said blood coagulation activity marker in spot urine and the level of said blood coagulation activity marker in 24 hour urine is at least 0.5. |
| Claim: |
48. The method of claim 1, wherein the Spearman rho correlation between the level of said blood coagulation activity marker in spot urine and the level of said blood coagulation activity marker in 24 hour urine is at least 0.9. |
| Claim: |
49. The method of claim 1, said label being capable of developing a label color, wherein a first visible color, attributable at least in part to said label color, is observable in step iv) when the marker is present in a first amount which is above the cut-off point, and a second and a visually determinably different visible color is observable when the marker is present in a second amount which is below the cut-off point. |
| Claim: |
50. The method of claim 49, in which the amount of the blood coagulation activity marker present in said spot urine sample is visually determined by visually discriminating between the first visible color indicating the amount of the marker to be above the cut-off point and the second visible color indicating the amount of the marker to be less than the cut-off point. |
| Claim: |
51. The method of claim 1, wherein the cut-off point is further based on previously determined correlations between (1) the amount of the marker in spot urine samples and the amount of the marker in plasma samples, and (2) the amount of the marker in plasma samples and the coagulation state of an individual of known coagulation state. |
| Claim: |
52. The method of claim 51, wherein correlation (1) is further based on previously determined correlations between (1a) the amount of the marker in spot urine samples and the amount of the marker in 24 hour urine samples, and (1b) the amount of the marker in 24 hour urine samples and the amount of the marker in plasma samples. |
| Claim: |
53. The method of claim 1 wherein at least a part of said spot urine sample is applied to an application zone of an extended solid phase, at least part of said applied spot urine sample is transferred to a detection zone of said extended solid phase, and said determining step is practiced on the at least part of said transferred spot urine sample present in said detection zone. |
| Claim: |
54. The method of claim 49 in which the spot urine sample is applied to the application zone of an assay device, at least part of such sample is conducted into a detection zone of said assay device, and the color change from said first color to said second color is observable in the detection zone, said detection zone comprising at least part of said spot urine sample, and said detection zone comprising no more than a single spot urine sample. |
| Claim: |
55. The method of claim 50 in which the spot urine sample is applied to the application zone of an assay device, at least part of such sample is conducted into a detection zone of said assay device, and the color change is visually observed in the detection zone, said detection zone comprising at least part of said spot urine sample, and said detection zone comprising no more than a single spot urine sample. |
| Claim: |
56. The method of claim 1 wherein the label is gold. |
| Current U.S. Class: |
435/13 |
| Current International Class: |
12 |
| رقم الانضمام: |
edspap.20100129841 |
| قاعدة البيانات: |
USPTO Patent Applications |